Insmed's anti-inflammatory drug wins breakthrough status; Kyowa Kirin backs new fund from 4BIO Capital
→ A mixed mid-stage readout of Insmed‘s anti-inflammatory drug, INS1007, read more like a win given the low expectations for the trial back in February. Now, the FDA has stamped the drug with a vote of confidence, granting it breakthrough therapy status for the treatment of adult patients with non-cystic fibrosis bronchiectasis for reducing exacerbations. The drug, now christened brensocatib, is an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.